Friday, August 6, 2010

New “Trading Alert” to be Released Monday, August 9 Before Open:  This is your one and only alert you will get.  We will release another new “Trading Alert” this coming Monday before the open.  As usual, we will email all members the report before the open, but you may want to also check our website at www.TheGreenBaron.com about 30 minutes before trading begins for the symbol.  Results for our “Trading Alerts” have been extraordinary, and we believe our string of big winners will continue.  Try to get in early!!!

 

 “Trading Alert” Update

A5 Laboratories, Inc.

(BB: AFLB)

 AFLB Rallies to hit $1.00 Per Share on Record Volume of 447,055 shares up as much as 13.6% in Three Days from our Profile Price of .88

Before the open of trading on Tuesday, August 3, The Green Baron Report released its new “Trading Alert” A5 Laboratories, Inc. (BB: AFLB).  Volume has steadily increased all week and now the price of AFLB has improved as it hit $1.00 per share yesterday.  Our results would be even better if we could have taken the bid price from Monday’s close of .84, but the last trade the previous day was on the offer at .88 per share.  Regardless, this stock looks like it is under heavy accumulation.

News from Aug 3, 2010

MONTREAL, QUEBEC -- (MARKET WIRE) -- 08/03/10 -- A5 Laboratories Inc. (A5 Labs) (OTCBB: AFLB) is pleased to provide an update on the company's business development activities for the month of July.

On July 5, 2010 the company closed the acquisition of the Contract Research Organization (CRO) and laboratory assets as well as intellectual property relating to a method for the production of interferon products. Subsequently, the company entered into agreements with two CRO customers to provide a comprehensive range of services.

Most recently A5 Labs submitted a provisional patent application to protect its technology for the production of interferon-based products. A5 Labs' lead product, VI-1718, has potential broad based applications for the treatment of certain types of cancer as well as multiple sclerosis and viral infections. During the month of July the company secured over $250,000 in equity financing.

Dr. Richard Azani, President and CEO of A5 said "I am very excited about the progress of our company in its first month of operations as a public entity. The filing of our patent was a crucial step, but equally important, the pharmaceutical companies are validating our ability to provide top notch services by entering into contracts with us and the investment community is validating our viability as a public company by providing us early financing. We look forward to expanding our management team and continuing to develop our production technology towards commercialization of interferon-based products in the coming months."

About A5 Labs:

A5 Labs is a contract research based organization servicing the pharmaceutical and biotechnology companies in North America. The company utilizes its research capabilities to license and acquire novel biotechnology products for development and commercialization.

Safe Harbor Statement:

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to A5 or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the amount of sales of A5's products, the competitive environment within the industry, the ability of A5 to continue to expand its operations, the level of costs incurred in connection with A5's expansion efforts, economic conditions in the industry and the financial strength of A5's customers and suppliers. A5 does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.

Contacts:

A5 Laboratories Inc.

Investor Relations

1-877-331-8777

ir@a5labs.com

 

DEFINITION: Green Baron “Trading Alert”

"Trading Alert" – A stock introduced to our members supported by research provided by a respected third party.  These are companies that we believe are worthy of investment, and we expect a big move up particularly in the extreme short-term.  These stocks have not been thoroughly researched by Green Baron staff, and therefore are not supported by a more in-depth profile.  Under the sub-section “Trading Alerts” on our website and our reports, we will provide a link to the independent research or BUY recommendation, a short description of the Company, and in some cases, we will conduct a Green Baron audio-taped webcast interview to allow a key person discuss the merits of the Company.

Compensation and Other Disclosures

All material listed within was based upon information supplied by the company or from other sources believed to be reliable. This information contains forward-looking statements that involve risks and uncertainties. A company’s actual results could differ materially from those described within. We recommend you use the information provided as an initial starting point for conducting your own research on these companies in order to determine your own personal opinion before investing. We disclaim any and all liability as to the completeness or accuracy of the information and for any omissions of material facts.  Evergreen Marketing, Inc., parent company of The Green Baron Report, has receives U.S. $4,500 for its coverage of companies as a “Trading Alert”.